Genzyme Corp. is facing a probable consent decree as the FDA steps in to enforce compliance efforts at its problem-plagued Allston Landing manufacturing facility, yet another black mark for the Cambridge, Mass.-based firm since the plant was shut down temporarily last year to resolve viral contamination affecting products in its lucrative enzyme replacement franchise. (BioWorld Today) Read More
